Regarding MSI disease and its association with BRAF mutations, the SEAMARK phase II trial is comparing a combination of encorafenib and cetuximab plus pembrolizumab, with pembrolizumab in monotherapy in untreated BRAF V600E-mutated MSI CRC patients (NCT05217446). The gene discussed is BRAF; the disease is colorectal carcinoma.